(ISRG) Intuitive Surgical - Overview
Stock: Surgical System, Ion Biopsy, Stapling Instruments, Support Services
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 34.5% |
| Relative Tail Risk | -12.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.47 |
| Alpha | -35.27 |
| Character TTM | |
|---|---|
| Beta | 1.194 |
| Beta Downside | 1.204 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.63% |
| CAGR/Max DD | 0.88 |
Description: ISRG Intuitive Surgical January 26, 2026
Intuitive Surgical (ISRG) designs, manufactures, and markets the da Vinci Surgical System-a robotic platform for minimally invasive procedures-and the Ion endoluminal system, which expands the company’s reach into bronchoscopic lung biopsies. Its product suite also includes stapling, energy, and core instruments, along with training pathways, 24/7 technical support, and data-driven service monitoring, sold primarily through direct capital and clinical sales teams.
Key recent metrics (FY 2023): revenue of $6.2 billion, up 12% year-over-year; operating margin of ≈30%; ~8,000 da Vinci systems installed globally, with a 5% quarterly growth in new installations; Ion system shipments rose 45% YoY, reflecting early adoption in pulmonary diagnostics. The company’s cash conversion cycle remains under 30 days, supporting its aggressive R&D spend of roughly $1.3 billion (≈21% of revenue).
Sector drivers that shape ISRG’s outlook include a rapidly aging U.S. and international population, increasing demand for outpatient and minimally invasive surgeries, and favorable reimbursement trends for robotic procedures. Competition from emerging robotic platforms and potential regulatory shifts in device approval timelines constitute material risks that could affect adoption rates.
For a deeper quantitative view, consider reviewing the detailed analytics available on the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 2.86b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 8.63 > 1.0 |
| NWC/Revenue: 66.79% < 20% (prev 64.24%; Δ 2.55% < -1%) |
| CFO/TA 0.15 > 3% & CFO 2.96b > Net Income 2.86b |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 4.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (360.4m) vs 12m ago -0.96% < -2% |
| Gross Margin: 66.06% > 18% (prev 0.67%; Δ 6539 % > 0.5%) |
| Asset Turnover: 52.71% > 50% (prev 44.34%; Δ 8.37% > 0%) |
| Interest Coverage Ratio: 25.06 > 6 (EBITDA TTM 3.68b / Interest Expense TTM 90.4m) |
Altman Z'' 4.16
| A: 0.35 (Total Current Assets 8.53b - Total Current Liabilities 1.80b) / Total Assets 19.35b |
| B: 0.33 (Retained Earnings 6.42b / Total Assets 19.35b) |
| C: 0.12 (EBIT TTM 2.27b / Avg Total Assets 19.10b) |
| D: 0.0 (Book Value of Equity 0.0 / Total Liabilities 2.31b) |
| Altman-Z'' Score: 4.16 = AA |
What is the price of ISRG shares?
Over the past week, the price has changed by -3.19%, over one month by -17.66%, over three months by -10.89% and over the past year by -17.05%.
Is ISRG a buy, sell or hold?
- StrongBuy: 14
- Buy: 8
- Hold: 10
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the ISRG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 611.8 | 25.3% |
| Analysts Target Price | 611.8 | 25.3% |
| ValueRay Target Price | 532.2 | 9% |
ISRG Fundamental Data Overview February 02, 2026
P/E Forward = 47.8469
P/S = 17.9589
P/B = 8.899
P/EG = 2.7875
Revenue TTM = 10.06b USD
EBIT TTM = 2.27b USD
EBITDA TTM = 3.68b USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 180.75b USD (180.75b + (null Debt) - (null CCE))
Interest Coverage Ratio = 25.06 (Ebit TTM 2.27b / Interest Expense TTM 90.4m)
EV/FCF = 79.58x (Enterprise Value 180.75b / FCF TTM 2.27b)
FCF Yield = 1.26% (FCF TTM 2.27b / Enterprise Value 180.75b)
FCF Margin = 22.57% (FCF TTM 2.27b / Revenue TTM 10.06b)
Net Margin = 28.38% (Net Income TTM 2.86b / Revenue TTM 10.06b)
Gross Margin = 66.06% ((Revenue TTM 10.06b - Cost of Revenue TTM 3.42b) / Revenue TTM)
Gross Margin QoQ = 66.56% (prev 66.36%)
Tobins Q-Ratio = 9.34 (Enterprise Value 180.75b / Total Assets 19.35b)
Interest Expense / Debt = unknown (Interest Expense 90.4m / Debt none)
Taxrate = 16.34% (156.1m / 955.6m)
NOPAT = 1.90b (EBIT 2.27b * (1 - 16.34%))
Current Ratio = 4.73 (Total Current Assets 8.53b / Total Current Liabilities 1.80b)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 3.68b)
Debt / FCF = unknown (Net Debt none / FCF TTM 2.27b)
Total Stockholder Equity = 17.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.96% (Net Income 2.86b / Total Assets 19.35b)
RoE = 16.72% (Net Income TTM 2.86b / Total Stockholder Equity 17.08b)
RoCE = 12.91% (EBIT 2.27b / Capital Employed (Total Assets 19.35b - Current Liab 1.80b))
RoIC = 10.96% (NOPAT 1.90b / Invested Capital 17.29b)
WACC = 10.32% (E(180.75b)/V(180.75b) * Re(10.32%) + (debt-free company))
Discount Rate = 10.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.31%
[DCF Debug] Terminal Value 67.42% ; FCFF base≈1.60b ; Y1≈1.40b ; Y5≈1.13b
Fair Price DCF = 40.18 (EV 14.24b - Net Debt 0.0 = Equity 14.24b / Shares 354.5m; r=10.32% [WACC]; 5y FCF grow -15.34% → 2.90% )
EPS Correlation: 97.03 | EPS CAGR: 23.98% | SUE: 2.02 | # QB: 3
Revenue Correlation: 98.06 | Revenue CAGR: 19.11% | SUE: 2.17 | # QB: 6
EPS next Quarter (2026-03-31): EPS=2.12 | Chg30d=+0.002 | Revisions Net=-2 | Analysts=27
EPS current Year (2026-12-31): EPS=10.02 | Chg30d=+0.322 | Revisions Net=+19 | Growth EPS=+12.2% | Growth Revenue=+14.6%
EPS next Year (2027-12-31): EPS=11.44 | Chg30d=+0.280 | Revisions Net=+16 | Growth EPS=+14.1% | Growth Revenue=+13.6%